Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Santen

This page shows the latest Santen news and features for those working in and with pharma, biotech and healthcare.

AbbVie's 'The Story of HS' wins at PMEA 2016

AbbVie's 'The Story of HS' wins at PMEA 2016

off competition from Novartis, Santen UK and Tillotts Pharma UK.

Latest news

  • NICE no for new eye disease drug NICE no for new eye disease drug

    NICE's preliminary recommendation has been to ask Santen Pharmaceutical for more information on Ikervis (ciclosporin) for treating severe keratitis in adults with dry eye disease which has not improved despite

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    The final two drugs to feature in the list of positive opinions were Santen's Ikervis (ciclosporin) for the treatment of the eye condition severe keratitis and MDCO's Raplixa (human

  • Meeting with resistance

    Low-grade B-cell lymphoma; mantle cell lymphoma. Japan. Diquafosol. Diquas Ophthalmic Solution 3% (Santen Pharmaceutical).

  • Inspire drops cystic fibrosis programme

    net sales of Diquas (diquafosol) for dry eye, which is marketed in Japan by Santen but has not been approved in the US.

  • Thin on the ground

    UK. Dorzolamide/timolol. Cosopt (Santen Pharmaceutical Co). Glaucoma and ocular hypertension. Japan.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    653. Merck &Co / Santen. Asset / product acquisition. 2. Ophthalmology products in Japan, Europe and Asia Pacific with sales of $400m.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Not content with the Bayer deals, Merck &Co also divested its ophthalmic business (mainly Timolol) in Japan, Asia Pacific and Europe to its licensee Santen.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Luis Iglesias heads Santen EMEA Luis Iglesias heads Santen EMEA

    His promotion sees him succeed Shigeo Taniuchi. Luis Iglesias has been promoted as Santen’s EMEA head, a move that sees him succeed Shigeo Taniuchi - who returns to Japan to become ... Iglesias initially joined Santen in 2017 as its senior vice

  • Paolo Casati named as general manager of Santen Italy Paolo Casati named as general manager of Santen Italy

    Has over 30 years of experience in the sector. Eye care specialist Santen Pharma has appointed Paolo Casati as general manager of its Italian subsidiary. ... I am very excited to join the team to establish Santen Italy as one of the major companies of

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Healthcircle

    Novo Nordisk. Otsuka. Pfizer. Roche. Santen. Santhera. Schwabe. Pelviva. Unicough.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...

Quick links

Infographics

Multimedia